Brooks AD - Search Results

1

Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins.

Tewary P, Brooks AD, Xu YM, Wijeratne EMK, Babyak AL, Back TC, Chari R, Evans CN, Henrich CJ, Meyer TJ, Edmondson EF, de Aquino MTP, Kanagasabai T, Shanker A, Gunatilaka AAL, Sayers TJ. Tewary P, et al. Among authors: brooks ad. Cancer Res. 2021 Jun 15;81(12):3374-3386. doi: 10.1158/0008-5472.CAN-20-2634. Epub 2021 Apr 9. Cancer Res. 2021. PMID: 33837043 Free PMC article.

2

Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras.

Fenton RG, Hixon JA, Wright PW, Brooks AD, Sayers TJ. Fenton RG, et al. Among authors: brooks ad. Cancer Res. 1998 Aug 1;58(15):3391-400. Cancer Res. 1998. PMID: 9699671

3

Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.

Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R, Wiltrout RH. Sayers TJ, et al. Among authors: brooks ad. J Immunol. 1998 Oct 15;161(8):3957-65. J Immunol. 1998. PMID: 9780164

4

IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.

Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JM, Wiltrout RH. Lee JK, et al. Among authors: brooks ad. J Immunol. 2000 Jan 1;164(1):231-9. doi: 10.4049/jimmunol.164.1.231. J Immunol. 2000. PMID: 10605016

5

T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas.

Sayers TJ, Brooks AD, Seki N, Smyth MJ, Yagita H, Blazar BR, Malyguine AM. Sayers TJ, et al. Among authors: brooks ad. J Leukoc Biol. 2000 Jul;68(1):81-6. J Leukoc Biol. 2000. PMID: 10914493

6

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ. Seki N, et al. Among authors: brooks ad. J Immunol. 2002 Apr 1;168(7):3484-92. doi: 10.4049/jimmunol.168.7.3484. J Immunol. 2002. PMID: 11907109

7

Study of diverse mechanisms of cell-mediated cytotoxicity in gene-targeted mice using flow cytometric cytotoxicity assay.

Malyguine A, Derby E, Brooks A, Reddy V, Baseler M, Sayers T. Malyguine A, et al. Immunol Lett. 2002 Aug 1;83(1):55-9. doi: 10.1016/s0165-2478(02)00048-2. Immunol Lett. 2002. PMID: 12057855

8

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.

Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ. Seki N, et al. Among authors: brooks ad. Cancer Res. 2003 Jan 1;63(1):207-13. Cancer Res. 2003. PMID: 12517799

9

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ. Sayers TJ, et al. Among authors: brooks ad. Blood. 2003 Jul 1;102(1):303-10. doi: 10.1182/blood-2002-09-2975. Epub 2003 Mar 13. Blood. 2003. PMID: 12637321 Free article.

10

Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis.

Brooks AD, Sayers TJ. Brooks AD, et al. Cancer Immunol Immunother. 2005 May;54(5):499-505. doi: 10.1007/s00262-004-0595-8. Epub 2004 Dec 22. Cancer Immunol Immunother. 2005. PMID: 15614529 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

119 results

Search Page

Filters